Outcomes research - where does the US FDA stand? Nancy JW Lewis Newsletter Article 17 February 2013 Pages: 3 - 3
More evaluations needed before shared care is adopted Newsletter Article 17 February 2013 Pages: 5 - 5
Antenatal corticosteroid use - a rare example of cost-effective technology Newsletter Article 17 February 2013 Pages: 6 - 6
Economic considerations in preventing NSAID-induced GI toxicity Newsletter Article 17 February 2013 Pages: 6 - 6
Looking at the economic burden of rheumatoid diseases Newsletter Article 17 February 2013 Pages: 6 - 7
Better outcomes with zidovudine vs zalcitabine for AIDS Newsletter Article 17 February 2013 Pages: 8 - 8
Surfactant improves neonatal survival without increasing cost Newsletter Article 17 February 2013 Pages: 9 - 9
Outcomes of conservative treatment of angina in the elderly Newsletter Article 17 February 2013 Pages: 10 - 10
Salmeterol more effective than salbutamol in asthma management Newsletter Article 17 February 2013 Pages: 11 - 11
Variation in the impact of indirect costs on healthcare programmes Newsletter Article 17 February 2013 Pages: 12 - 13
